ArticleCancer control : journal of the Moffitt Cancer Center
Five-Year Survival and Determinants of Diffuse Large B-cell Lymphoma in Resource-Limited Settings: The Impact of HIV/AIDS in a Multi-Center Cohort Study.
Article in Cancer control : journal of the Moffitt Cancer Center. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundDiffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma and a leading cause of cancer-related mortality worldwide. Evidence on long-term survival and prognostic determinants remains limited, particularly among people living with HIV. This study evaluated survival outcomes and predictors of mortality among adults with DLBCL in Northwest Ethiopia.MethodsWe conducted a multicenter retrospective cohort study of consecutively enrolled adults with newly histologically confirmed DLBCL diagnosed between August 1, 2020, and July 31, 2025, at three referral hospitals in Northwest Ethiopia. Patients were followed from diagnosis until death, loss to follow-up, or study end. Overall survival (OS) was estimated using the Kaplan-Meier method. Cox proportional hazard regression was used to identify independent predictors of mortality. Subgroup analyses were performed depending on HIV status. Statistical significance was set at P ≤0.05.ResultsA total of 175 patients with DLBCL were included, of whom 31 (17.7%) were HIV-positive. The median survival time was 36 months (IQR: 21-49). The estimated 5-year OS was 25%. Advanced disease (stage IV; AHR = 2.7, 95% CI: 1.1-6.5), HIV-positive status (AHR = 2.3, 95% CI: 1.1-5.0), elevated serum lactate dehydrogenase (LDH) (≥2× upper limit of normal; AHR = 2.2, 95% CI: 1.0-4.9), and delayed initiation of chemotherapy (≥2 months; AHR = 2.6, 95% CI: 1.2-5.8) were independently associated with increased mortality. Among HIV-positive patients, neutropenic fever was the sole independent predictor of death (AHR = 4.3, 95% CI: 1.1-17.4).ConclusionsSurvival among patients with DLBCL in Northwest Ethiopia remains poor, particularly among those presenting with advanced disease, those living with HIV, those that have delayed treatment initiation, and those that have elevated serum LDH - all these parameters were independently associated with increased mortality. Strengthening diagnostic capacity, ensuring equitable access to immunochemotherapy, integrating HIV-oncology services, and prioritizing early treatment initiation are essential to improving outcome.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.